NEW YORK, Nov. 13, 2017 -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that Jonathan Eckard, Chief Scientific Affairs Officer, and Ben Taylor, President and Chief Financial Officer, will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference.
Event: Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
Date: November 30, 2017
Time: 1:35 PM EST
Location: Boston, Massachusetts
A live webcast of the presentation will be available in the “Investors” section of the Tyme website, www.tymeinc.com/investors. The webcast will be archived on the company website for 30 days following the presentation.
About Tyme
Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Tyme’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and the Company is preparing to initiate an additional Phase II clinical trial in pancreatic cancer. For more information, visit www.tymeinc.com.
Contacts
Tyme Inc.
Jonathan Eckard
Chief Scientific Affairs Officer
jon.eckard@tymeinc.com
ICR Healthcare
Investors
Stephanie Carrington
Stephanie.Carrington@icrinc.com
646-277-1282
6 Degrees
Media
Sarah Hall
shall@6degreespr.com
215-313-5638
